The policy stagnation of recent years, where change has been almost entirely focused on pricing, belies a history of significant structural shifts to ensure the program can better accommodate patient needs.
The system can innovate for patients, when it wants, but history shows it rarely involves HTA
May 31, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Australian medtech secures funds to advance real-time breast cancer surgery technology
February 13, 2026 - - Australian Biotech -
The Dispatched Podcast 'Week in Review' - 13 February
February 13, 2026 - - Podcast -
PBAC to reconsider broader vaccine funding after late addition to March agenda
February 13, 2026 - - Latest News -
Ten years of process 'improvements' is almost the point, says Anne Ruston
February 13, 2026 - - Latest News -
Senate scrutiny of PBS rules after Canberra family highlights lack of biologic access
February 12, 2026 - - Latest News -
There is no negotiation, yet, so be careful not to give the impression of conceding anything
February 11, 2026 - - Latest News -
Arrotex and Pfizer forge strategic pharmacy partnership for ENBREL in Australia
February 11, 2026 - - Latest News

